All In Biotech

Drug Trial Radar · NCT07789899

A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants

A Phase 1, Open-Label, Randomized, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations After a Single Dose in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Aug 18, 2026

Primary completion

Sep 7, 2027

Study completion Sep 7, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will compare two formulations of the investigational medicine GSK3862995B in healthy adults. The study aims to assess how the body absorbs and processes the medicine, and to evaluate its safety and tolerability.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • GSK3862995BDrug

    GSK3862995B will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-t)] of GSK3862995BTime frame: From pre-dose on Day 1 through Week 36
  2. Maximum Observed Serum Concentration (Cmax) of GSK3862995BTime frame: From pre-dose on Day 1 through Week 36
  3. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Week 49
  4. Number of Participants With Clinically Significant Changes in Laboratory Parameters, Vital Signs, and 12-Lead Electrocardiogram (ECG) FindingsTime frame: Up to Week 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Cambridge, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.